Skip to main content
Clinical Trials/NCT00168987
NCT00168987
Completed
Phase 4

Pilot Study: Randomized Controlled Trial on the Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors

Charite University, Berlin, Germany1 site in 1 country30 target enrollmentJanuary 2005

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Colorectal Neoplasms
Sponsor
Charite University, Berlin, Germany
Enrollment
30
Locations
1
Primary Endpoint
improvement of muscle function (hand grip strength, respiratory muscle function) at two months
Status
Completed
Last Updated
17 years ago

Overview

Brief Summary

Malnutrition is a frequent symptom of various malignant diseases and is frequently observed in patients with gastrointestinal tumors. Eicosapentanoic acid (EPA) has been introduced as specific and anticatabolic acting substrate in cancer patients. Only few randomized trials are available which investigated the effect of EPA in form of an EPA-enriched, protein- and energy-dense oral nutritional supplement mostly in patients with pancreatic carcinoma.

Therefore, the effect of an EPA-rich oral nutritional supplement for two months on functional state and quality of life in patients with other gastroenterological tumors and weight loss is investigated in this randomized prospective trial.

Registry
clinicaltrials.gov
Start Date
January 2005
End Date
June 2007
Last Updated
17 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • malignant disease: colorectal neoplasm, hepatocellular carcinoma, cholangiocarcinoma
  • palliative treatment of malignant disease: UICC stage \>1
  • impaired nutritional state: weight loss \> 5% body weight in the preceding 6 months or subjective global assessment grade B (moderately malnourished) or grade C (severely malnourished)
  • informed written consent

Exclusion Criteria

  • age \< 18 years
  • pregnancy
  • exclusive enteral or parenteral nutrition
  • taking of eicosapentanoic acid in form of fish oil capsules
  • contraindications for oral nutrition (i.e. ileus, uncontrollable vomiting)
  • terminal stage of disease with a life expectancy \< 3 months
  • missing or withdrawn consent
  • simultaneous participation in another trial

Outcomes

Primary Outcomes

improvement of muscle function (hand grip strength, respiratory muscle function) at two months

improvement of cognitive function at two months

improvement of quality of life at two months

Secondary Outcomes

  • tolerance of the oral nutritional supplement
  • improvement of nutritional state (body weight, muscle mass, body cell mass, phase angle, serum albumin)

Study Sites (1)

Loading locations...

Similar Trials